Digital newsroom

Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

EXACT SCIENCES HIGHLIGHTS THE OPPORTUNITY TO SEEK SCREENING WITH COLOGUARD® THROUGH TELEHEALTH

Message from Chairman & CEO, Kevin Conroy

FIGHT COLORECTAL CANCER RECEIVES GRANT FROM EXACT SCIENCES TO LAUNCH PROGRAM AIMED AT REDUCING PATIENT BARRIERS TO COLORECTAL CANCER SCREENING

New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-Negative or Node-Positive Early-Stage Breast Cancer

Dr. David Ahlquist, Co-Inventor of Cologuard, Named a Fellow of the National Academy of Inventors

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

Exact Sciences Presents Data on Blood-based Test for Detection of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation

Exact Sciences Presents New Stool-based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study

1 2 3 4 5 6 7 8 9